Breast cancer drug “surpasses” tamoxifenBMJ 2001; 323 doi: https://doi.org/10.1136/bmj.323.7326.1387a (Published 15 December 2001) Cite this as: BMJ 2001;323:1387
- Alex Vass
The British pharmaceutical company AstraZeneca claimed this week that “the established benefits of tamoxifen in early breast cancer have been surpassed by another treatment.”
Dr Jeffrey Tobias, consultant radiotherapist and oncologist at University College London Hospitals, who presented early results of a five year trial of the drug to the press this week, predicted that anastrozole (Aridex) would “knock tamoxifen off its poll position over the next 15 years.”
Data came from the ATAC (Aridex, tamoxifen alone or in combination) randomised trial of 9366 postmenopausal women with operable breast cancer. Recruitment took place in 21 countries, with over 3000 patients coming from the United Kingdom. Between 1996 and 2000, women who had completed surgery were randomised into one of three arms to compare tamoxifen, anastrozole, or a combination of both drugs.
Thirty three months into the five year …
Log in using your username and password
Log in through your institution
Register for a free trial to thebmj.com to receive unlimited access to all content on thebmj.com for 14 days.
Sign up for a free trial